Overview
TTRX market data
Price History
TTRX price chart · 1M
- O
- 10.07
- H
- 10.20
- L
- 10.07
- C
- 10.20
- Vol
- 651.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $10.07
- Previous Close
- $9.56
- Day High
- $10.20
- Day Low
- $10.07
- 52 Week High
- $11.52
- 52 Week Low
- $3.59
- 7 Day Return
- +3.24%
- 30 Day Return
- +28.63%
- 90 Day Return
- +104.20%
- 1 Year Return
- +184.12%
- Daily Notional Volume
- $6.6K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.70 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.57 – $26.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $293.7M · P/B 24.75.
Company News
Turn Therapeutics Publishes Peer-Reviewed Research Of GX-03 In Life.Benzinga · Aug 20, 2026, 12:06 PM
8-K filing — Turn Therapeutics Inc. (TTRX)SEC EDGAR · Aug 18, 2026, 12:30 PM
Turn Therapeutics Q2 EPS $(0.20) Misses $(0.02) EstimateBenzinga · Aug 12, 2026, 8:41 PM
Why Is Turn Therapeutics Stock Trading Higher Today?Benzinga · Jul 7, 2026, 6:25 PM
Turn Therapeutics Completes Comprehensive Interim Analysis Of Ongoing Adaptive Phase 2 Clinical Trial Evaluating GX-03 For Treatment Of Atopic DermatitisBenzinga · Jul 7, 2026, 12:15 PM
Turn Therapeutics To Present Data On Its Interim Analysis Of Its Current Adaptive Phase 2 Study Of GX-03 In Atopic DermatitisBenzinga · Jul 6, 2026, 8:05 PM
Turn Therapeutics shares are trading higher. The company announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating GX-03 in adults with atopic dermatitis.Benzinga · Jun 1, 2026, 7:44 PM
Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic DermatitisBenzinga · Jun 1, 2026, 12:36 PM